- USANA Health Sciences, Inc. (USNA, Financial) reported Q1 2025 net sales of $250 million, marking a 10% year-over-year increase.
- Net earnings for the quarter fell to $9.4 million, a decline of 43% from Q1 2024's $16.5 million.
- The company reiterated its fiscal year 2025 revenue outlook at $920 million to $1.0 billion.
USANA Health Sciences, Inc. (USNA) has released its financial results for the first quarter of 2025, showing a strong performance in net sales and a reiteration of its annual outlook despite challenges. Net sales for Q1 2025 reached $250 million, up from $228 million the previous year, reflecting a 10% growth, which translates to 12% growth in constant currency.
However, the company experienced a significant decline in net earnings, which stood at $9.4 million, compared to $16.5 million in the first quarter of 2024. Diluted earnings per share (EPS) also decreased to $0.49 from $0.86, with adjusted diluted EPS at $0.73, down from $0.86.
The Hiya division of the business showed promising results, with net sales reaching $37 million and 224,000 active monthly subscribers. This division is anticipated to continue its growth trajectory, with plans to introduce new products and strategic partnerships throughout the year.
During the first quarter, USANA repurchased 399,000 shares, investing $12 million in this initiative. By the end of the quarter, the company had $180 million in cash and cash equivalents and retained $49 million under the current share repurchase authorization.
USANA's outlook for the fiscal year 2025 remains optimistic, with projected consolidated net sales between $920 million and $1.0 billion, representing potential growth of 8% to 17%. The company remains vigilant about the uncertain global economic environment but expects continued demand for its products supported by its direct sales and Hiya's direct-to-consumer business models.
